Skip to content

All recalls FDA

FDADrugsRecalled Status: Ongoing

Fresenius Kabi USA, LLC recalls Naropin (ropivacaine hydrochloride Injection

Class IIofficial

FDA Class II

FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.

Hazard
Presence of Particulate Matter: Hair was found in products
Products
  • Naropin (ropivacaine hydrochloride Injection
Where it was sold

Nationwide within in the USA

Nationwide

Units affected
92,600 vials
About this recall
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05